Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 56Myelodysplastic Syndromes 14Leukemia 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Recurrence 4Leukemia, Myelomonocytic, Chronic 3Leukemia, Monocytic, Acute 3Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelomonocytic, Acute 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphoid 1Leukemia, Erythroblastic, Acute 1Hodgkin Disease 1Disease 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recurrence × CPX-351 × Clear all
NCT03826992 2026-02-18

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Children's Hospital Medical Center, Cincinnati

Phase 1 Recruiting
21 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02269579 2018-03-14

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

Jazz Pharmaceuticals

Phase 2 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02238925 2017-11-30

An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients

Jazz Pharmaceuticals

Phase 2 Completed
26 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00822094 2017-11-24

Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)

Jazz Pharmaceuticals

Phase 2 Completed
126 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡